Eva Van Rooij

List of Publications by Year in Descending Order

50 papers	12,652 citations	39 h-index	54 g-index
54 ext. papers	13,842 ext. citations	14.3 avg, IF	6.53 L-index

#	Paper	IF	Citations
50	Keeping the Heart Fitm2 during Chemotherapy. *Molecular Therapy*, **2019**, 27, 10-12	11.7	1
49	Single-Cell Sequencing of the Healthy and Diseased Heart Reveals Cytoskeleton-Associated Protein 4 as a New Modulator of Fibroblasts Activation. *Circulation*, **2018**, 138, 166-180	16.7	142
48	Controlled Release of RNAi Molecules by Tunable Supramolecular Hydrogel Carriers. *Chemistry - an Asian Journal*, **2018**, 13, 3501-3508	4.5	11
47	The Efficacy of Cardiac Anti-miR-208a Therapy Is Stress Dependent. *Molecular Therapy*, **2017**, 25, 694-704	11.7	16
46	Modulating microRNAs in cardiac surgery patients: Novel therapeutic opportunities?. *Pharmacology & Therapeutics*, **2017**, 170, 192-204	13.9	13
45	Tomo-Seq Identifies SOX9 as a Key Regulator of Cardiac Fibrosis During Ischemic Injury. *Circulation*, **2017**, 136, 1396-1409	16.7	47
44	Function and Therapeutic Potential of Noncoding RNAs in Cardiac Fibrosis. *Circulation Research*, **2016**, 118, 108-18	15.7	70
43	MicroRNA-214 antagonism protects against renal fibrosis. *Journal of the American Society of Nephrology: JASN*, **2014**, 25, 65-80	12.7	110
42	Meeting highlights from the 2013 European Society of Cardiology Heart Failure Association Winter Meeting on Translational Heart Failure Research. *European Journal of Heart Failure*, **2014**, 16, 6-14	12.3	0
41	MicroRNA mimicry blocks pulmonary fibrosis. *EMBO Molecular Medicine*, **2014**, 6, 1347-56	12	165
40	Endothelial apoptosis in pulmonary hypertension is controlled by a microRNA/programmed cell death 4/caspase-3 axis. *Hypertension*, **2014**, 64, 185-94	8.5	66
39	miR-25 in heart failure. *Circulation Research*, **2014**, 115, 610-2	15.7	13
38	Development of microRNA therapeutics is coming of age. *EMBO Molecular Medicine*, **2014**, 6, 851-64	12	441
37	Inhibition of miR-92a improves re-endothelialization and prevents neointima formation following vascular injury. *Cardiovascular Research*, **2014**, 103, 564-72	9.9	95
36	miRNA-21 is dysregulated in response to vein grafting in multiple models and genetic ablation in mice attenuates neointima formation. *European Heart Journal*, **2013**, 34, 1636-43	9.5	50
35	Transient but not genetic loss of miR-451 is protective in the development of pulmonary arterial hypertension. *Pulmonary Circulation*, **2013**, 3, 840-50	2.7	11
34	Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. *European Journal of Heart Failure*, **2013**, 15, 650-9	12.3	122

33	Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model. *Circulation*, **2013**, 128, 1066-75	16.7	237
32	Introduction to the series on microRNAs in the cardiovascular system. *Circulation Research*, **2012**, 110, 481-2	15.7	38
31	MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. *Nature Reviews Drug Discovery*, **2012**, 11, 860-72	64.1	475
30	A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. *Circulation Research*, **2012**, 111, 290-300	15.7	230
29	Developing microRNA therapeutics. *Circulation Research*, **2012**, 110, 496-507	15.7	387
28	Regulated expression of pH sensing G Protein-coupled receptor-68 identified through chemical biology defines a new drug target for ischemic heart disease. *ACS Chemical Biology*, **2012**, 7, 1077-83	4.9	43
27	A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. *Cell*, **2012**, 149, 671-83	30.2	277
26	Cardiac MicroRNAs **2012**, 341-351		
25	MicroRNA-214 protects the mouse heart from ischemic injury by controlling Ca□+ overload and cell death. *Journal of Clinical Investigation*, **2012**, 122, 1222-32	15.9	294
24	Inhibition of miR-15 protects against cardiac ischemic injury. *Circulation Research*, **2012**, 110, 71-81	15.7	392
23	The art of microRNA research. *Circulation Research*, **2011**, 108, 219-34	15.7	423
22	Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. *Circulation*, **2011**, 124, 1537-47	16.7	479
21	Therapeutic advances in MicroRNA targeting. *Journal of Cardiovascular Pharmacology*, **2011**, 57, 1-7	3.1	33
20	MiR-15 family regulates postnatal mitotic arrest of cardiomyocytes. *Circulation Research*, **2011**, 109, 670-9	15.7	335
19	Response to Thum et al.. *Journal of Clinical Investigation*, **2011**, 121, 462-463	15.9	5
18	Myocyte enhancer factor 2 and class II histone deacetylases control a gender-specific pathway of cardioprotection mediated by the estrogen receptor. *Circulation Research*, **2010**, 106, 155-65	15.7	42
17	MicroRNA regulation as a therapeutic strategy for cardiovascular disease. *Current Drug Targets*, **2010**, 11, 936-42	3	154
16	miRNAs as therapeutic targets in ischemic heart disease. *Journal of Cardiovascular Translational Research*, **2010**, 3, 280-9	3.3	46

15	Modulation of K-Ras-dependent lung tumorigenesis by MicroRNA-21. *Cancer Cell*, **2010**, 18, 282-93	24.3	491
14	Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice. *Journal of Clinical Investigation*, **2010**, 120, 3912-6	15.9	294
13	Searching for miR-acles in cardiac fibrosis. *Circulation Research*, **2009**, 104, 138-40	15.7	69
12	MicroRNA control of muscle development and disease. *Current Opinion in Cell Biology*, **2009**, 21, 461-9	9	290
11	A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance. *Developmental Cell*, **2009**, 17, 662-73	10.2	737
10	MicroRNAs flex their muscles. *Trends in Genetics*, **2008**, 24, 159-66	8.5	275
9	Toward microRNA-based therapeutics for heart disease: the sense in antisense. *Circulation Research* , **2008**, 103, 919-28	15.7	317
8	Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 13027-32	11.5	1411
7	The MEF2D transcription factor mediates stress-dependent cardiac remodeling in mice. *Journal of Clinical Investigation*, **2008**, 118, 124-32	15.9	177
6	Control of stress-dependent cardiac growth and gene expression by a microRNA. *Science*, **2007**, 316, 575-9	33.3	1357
5	microRNAs put their signatures on the heart. *Physiological Genomics*, **2007**, 31, 365-6	3.6	43
4	MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. *Journal of Clinical Investigation*, **2007**, 117, 2369-76	15.9	410
3	Regulation of cardiac stress signaling by protein kinase d1. *Molecular and Cellular Biology*, **2006**, 26, 3875-88	4.8	138
2	A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 18255-60	11.5	1263
1	MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction. *Circulation Research*, **2004**, 94, e18-26	15.7	88